Search:
Filter:
Post type:
Sort:
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.
Victory Medical Center Pharmacy issued a voluntary recall for three lots of its compounded glutathione vials due to elevated endotoxin levels.
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
United States District Court District of New Jersey USA v Frank Incognito Judgment Filed July 2026 Read the document.
United States District Court District of New Jersey USA v Frank Incognito Plea Agreement Filed February 2026 Read the document.
United States District Court District of New Jersey USA v Frank Incognito Information Filed February 2026 Read the document.
United States District Court Western District of Virginia USA v Bryce Cleveland Plea Agreement Filed July 2026 Read the document.
United States District Court Western District of Virginia USA v Bryce Cleveland Indictment Filed July 2024 Read the document.
The man was sentenced to six years for deceptively marketing “research use only” chemicals, which the judge said left “an incredible trail of harm.”